Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

Articles and Videos

Loading...
June 22, 2022
InMed Pharmaceuticals publicizes new peer-reviewed study
New academic journal spotlights potential for rare cannabinoids to treat skin conditions Read full article via Mugglehead Magazine. Excerpt: Less popular cannabinoids such as tetrahydrocannabivarin...
Read More
June 17, 2022
Benzinga All Access: Guest Speaker Shane Johnson, BayMedica GM
Dr. Shane Johnson, SVP and GM of BayMedica, InMed's subsidiary, joins Benzinga's All Access Conference on June 17, 2022. Dr. Johnson talks about how manufacturing...
Source: Benzinga All Access
Read More
June 14, 2022
Scientific study on the biological activity of rare cannabinoids and their potential role on skin conditions published in peer-reviewed article
A peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences....
Read More
May 17, 2022
The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids like...
Read More
April 28, 2022
Edison: Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids
InMed featured in this article about the different cannabinoid manufacturing technologies that are shaping the industry. The article by Edison also talks about the cannabinoid...
Read More
April 28, 2022
Fly exclusive interview with CEO Eric Adams
Leading digital financial news publisher "The Fly" gets an update on the launch of InMed's rare cannabinoid products and progress of our programs from CEO Eric A....
Read More
« Previous 1 … 3 4 5 6 7 … 18 Next »

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • INM-900 Series for Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*